$BEAM
Beam Therapeutics Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024091242 Filed on August 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $14.27M $11.77M
YoY Change -17.01% -41.48%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $26.52M $29.63M
YoY Change 4.35% 20.16%
% of Gross Profit
Research & Development $94.26M $87.04M
YoY Change -5.79% -10.83%
% of Gross Profit
Depreciation & Amortization $5.475M $5.576M
YoY Change 5.55% 15.78%
% of Gross Profit
Operating Expenses $120.8M $116.7M
YoY Change -3.74% -4.58%
Operating Profit -$106.5M -$104.9M
YoY Change -1.63% 2.69%
Interest Expense $9.863M $12.10M
YoY Change 59.6% -29.63%
% of Operating Profit
Other Income/Expense, Net $9.836M $13.88M
YoY Change -19.24% 539.47%
Pretax Income -$96.67M -$91.01M
YoY Change 0.6% 9.95%
Income Tax $0.00 $39.00K
% Of Pretax Income
Net Earnings -$96.67M -$91.05M
YoY Change 0.6% 10.0%
Net Earnings / Revenue -677.47% -773.45%
Basic Earnings Per Share -$1.17 -$1.11
Diluted Earnings Per Share -$1.17 -$1.11
COMMON SHARES
Basic Shares Outstanding 82.42M 82.31M
Diluted Shares Outstanding 82.41M 82.31M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $925.8M $1.008B
YoY Change -8.84% -6.04%
Cash & Equivalents $230.2M $292.8M
Short-Term Investments $695.6M $715.4M
Other Short-Term Assets $19.78M $21.28M
YoY Change -17.94% -2.36%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $945.5M $1.029B
YoY Change -9.04% -5.97%
LONG-TERM ASSETS
Property, Plant & Equipment $113.5M $117.5M
YoY Change -10.99% -51.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.078M $1.323M
YoY Change -59.35% -92.13%
Total Long-Term Assets $225.8M $231.8M
YoY Change -10.02% -10.52%
TOTAL ASSETS
Total Short-Term Assets $945.5M $1.029B
Total Long-Term Assets $225.8M $231.8M
Total Assets $1.171B $1.261B
YoY Change -9.23% -6.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.812M $4.429M
YoY Change 19.99% -35.68%
Accrued Expenses $64.71M $79.78M
YoY Change 20.49% 62.78%
Deferred Revenue $89.33M $84.93M
YoY Change -41.8% -38.96%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $166.2M $177.3M
YoY Change -24.56% -15.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $481.0K $679.0K
YoY Change -54.1% -99.8%
Total Long-Term Liabilities $481.0K $679.0K
YoY Change -54.1% -99.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $166.2M $177.3M
Total Long-Term Liabilities $481.0K $679.0K
Total Liabilities $380.1M $407.2M
YoY Change -25.71% -24.91%
SHAREHOLDERS EQUITY
Retained Earnings -$1.500B -$1.400B
YoY Change 15.38% 16.67%
Common Stock $826.0K $824.0K
YoY Change 4.03% 5.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $791.3M $854.1M
YoY Change
Total Liabilities & Shareholders Equity $1.171B $1.261B
YoY Change -9.23% -6.84%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$96.67M -$91.05M
YoY Change 0.6% 10.0%
Depreciation, Depletion And Amortization $5.475M $5.576M
YoY Change 5.55% 15.78%
Cash From Operating Activities -$88.12M -$83.01M
YoY Change -1.87% -1.96%
INVESTING ACTIVITIES
Capital Expenditures $1.577M $1.961M
YoY Change -80.04% -87.88%
Acquisitions
YoY Change
Other Investing Activities $26.28M $89.45M
YoY Change -1242.39% -453.55%
Cash From Investing Activities $24.70M $87.49M
YoY Change -339.79% -310.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.262M 133.0K
YoY Change -96.56% -99.88%
NET CHANGE
Cash From Operating Activities -88.12M -83.01M
Cash From Investing Activities 24.70M 87.49M
Cash From Financing Activities 1.262M 133.0K
Net Change In Cash -62.16M 4.617M
YoY Change -1.95% -124.81%
FREE CASH FLOW
Cash From Operating Activities -$88.12M -$83.01M
Capital Expenditures $1.577M $1.961M
Free Cash Flow -$89.70M -$84.97M
YoY Change -8.19% -15.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
11953000
beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
26039000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001745999
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseMember
CY2023Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39208
dei Entity Registrant Name
EntityRegistrantName
Beam Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-5238376
dei Entity Address Address Line1
EntityAddressAddressLine1
238 Main Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
327-8775
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
BEAM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
82415619
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
292763000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
435895000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
715402000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
753981000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
21275000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
21167000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
1029440000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1211043000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
117470000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
124960000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6154000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8719000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
106879000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
112846000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1323000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2146000
CY2024Q2 us-gaap Assets
Assets
1261266000
CY2023Q4 us-gaap Assets
Assets
1459714000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4429000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1617000
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
67138000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
111664000
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
8200000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
10800000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
84925000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
68706000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12641000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12778000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
177333000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
205565000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
152596000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
159911000
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1077000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
2723000
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
75487000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
109888000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
679000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
298000
CY2024Q2 us-gaap Liabilities
Liabilities
407172000
CY2023Q4 us-gaap Liabilities
Liabilities
478385000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82386210
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
82386210
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
81632496
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81632496
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
824000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
816000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2233989000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2169798000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1110000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
604000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1379609000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1189889000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
854094000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
981329000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1261266000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1459714000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11772000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20116000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19182000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
44324000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
87041000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97608000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
171859000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
197254000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29626000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24656000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
56350000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48146000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
116667000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
122264000
us-gaap Operating Expenses
OperatingExpenses
228209000
us-gaap Operating Expenses
OperatingExpenses
245400000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-104895000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-102148000
us-gaap Operating Income Loss
OperatingIncomeLoss
-209027000
us-gaap Operating Income Loss
OperatingIncomeLoss
-201076000
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
5500000
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-900000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2600000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4700000
CY2024Q2 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-7586000
CY2023Q2 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
6148000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-10939000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-6649000
CY2024Q2 beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1779000
CY2023Q2 beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-2171000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1646000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1875000
CY2024Q2 beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
14190000
beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
21914000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13883000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
19372000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
19346000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
21840000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-91012000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-82776000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-189681000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-179236000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-91051000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-82776000
us-gaap Net Income Loss
NetIncomeLoss
-189720000
us-gaap Net Income Loss
NetIncomeLoss
-179236000
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-189000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1250000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1714000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
415000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-91240000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-84026000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-191434000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-178821000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.11
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.41
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82312467
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82312467
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76335175
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76335175
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82005550
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82005550
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74315721
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74315721
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
733474000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1708000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23917000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3392000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1665000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-96460000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
761506000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26278000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
702000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1250000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-82776000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
811643000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
981329000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1398000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29281000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1676000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1525000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-98669000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
913490000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31604000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
240000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-189000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-91051000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
854094000
us-gaap Profit Loss
ProfitLoss
-189720000
us-gaap Profit Loss
ProfitLoss
-179236000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11007000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9463000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
12502000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
14505000
us-gaap Share Based Compensation
ShareBasedCompensation
60885000
us-gaap Share Based Compensation
ShareBasedCompensation
50195000
beam Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
4755000
beam Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
4829000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2600000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4700000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1646000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1875000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-10939000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-6649000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-714000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6476000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3057000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2765000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-43761000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-10154000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-6241000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4054000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-18182000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-42824000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
539000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
969000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-182756000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-194484000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4399000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22195000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
329714000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
657359000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
368142000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
663525000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
34029000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16029000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
201623000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1398000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1708000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
247000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
284000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1220000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1916000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4094000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3030000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
205958000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-145697000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4555000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
444614000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
245521000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
298917000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
240966000
us-gaap Interest Paid Net
InterestPaidNet
22000
us-gaap Interest Paid Net
InterestPaidNet
112000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
521000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5634000
beam Operating Lease Liabilities Increase Decrease
OperatingLeaseLiabilitiesIncreaseDecrease
-1273000
beam Operating Lease Liabilities Increase Decrease
OperatingLeaseLiabilitiesIncreaseDecrease
392000
beam Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
384000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1400000000
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
1000000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, stock-based compensation, contingent consideration liabilities, success payments and certain judgments regarding revenue recognition. Actual results could differ from these estimates.</span></p>
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
292763000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
225544000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6154000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15422000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
298917000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
240966000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
178659000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
175142000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
61189000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
50182000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
117470000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
124960000
CY2024Q2 us-gaap Depreciation
Depreciation
5576000
CY2023Q2 us-gaap Depreciation
Depreciation
4816000
us-gaap Depreciation
Depreciation
11007000
us-gaap Depreciation
Depreciation
9463000
CY2024Q2 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-7586000
CY2023Q2 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
6148000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-10939000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-6649000
CY2024Q2 beam Available For Sale Debt Securities And Equity Securities Fv Ni Amortized Cost Basis
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis
716512000
CY2024Q2 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes
60000
CY2024Q2 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Loss Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes
1170000
CY2024Q2 beam Available For Sale Debt Securities And Equity Securities Fv Ni
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi
715402000
CY2023Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni Amortized Cost Basis
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis
753377000
CY2023Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes
1077000
CY2023Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Loss Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes
473000
CY2023Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi
753981000
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0
CY2024Q2 beam Accrued Contingent Obligation License Agreement Current
AccruedContingentObligationLicenseAgreementCurrent
21640000
CY2023Q4 beam Accrued Contingent Obligation License Agreement Current
AccruedContingentObligationLicenseAgreementCurrent
43280000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9635000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21774000
CY2024Q2 beam Accrued Research Costs
AccruedResearchCosts
6896000
CY2023Q4 beam Accrued Research Costs
AccruedResearchCosts
9804000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3724000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3468000
CY2024Q2 beam Accrued Process Development And Manufacturing Costs
AccruedProcessDevelopmentAndManufacturingCosts
1703000
CY2023Q4 beam Accrued Process Development And Manufacturing Costs
AccruedProcessDevelopmentAndManufacturingCosts
4697000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
23540000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
28641000
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
67138000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
111664000
CY2024Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
20200000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31604000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26278000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60885000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50195000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8276033
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2260584
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
24.6
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
184634
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.37
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
213581
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
50.64
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10138402
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
38.99
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5768050
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
38.87
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.94
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13547466
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11090234
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-91051000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-82776000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-189720000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-179236000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82312467
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82312467
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76335175
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76335175
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82005550
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82005550
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74315721
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74315721
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.11
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.41
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
beam Number Of Founder Shareholders
NumberOfFounderShareholders
3

Files In Submission

Name View Source Status
0000950170-24-091242-index-headers.html Edgar Link pending
0000950170-24-091242-index.html Edgar Link pending
0000950170-24-091242.txt Edgar Link pending
0000950170-24-091242-xbrl.zip Edgar Link pending
beam-20240630.htm Edgar Link pending
beam-20240630.xsd Edgar Link pending
beam-ex10_3.htm Edgar Link pending
beam-ex31_1.htm Edgar Link pending
beam-ex31_2.htm Edgar Link pending
beam-ex32_1.htm Edgar Link pending
beam-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
beam-20240630_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable